Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial

Autor: Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen, Maike Nickelsen, Ofer Shpilberg, Mathias Witzens-Harig, Frank Griesinger, Beate Krammer-Steiner, Andreas Neubauer, Peter de Nully Brown, Massimo Federico, Bertram Glass, Norbert Schmitz, Gerald Wulf, Lorenz Truemper, Moritz Bewarder, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Marianne Engelhard, Heinz Schmidberger, Jochen Fleckenstein, Christian Berdel, Markus Loeffler, Marita Ziepert, on behalf of the German Lymphoma Alliance (GLA)

Publikováno v: HemaSphere, Vol 7, Iss 7, p e917 (2023)

UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were randomized to

Externí odkaz: https://doaj.org/article/f39990c175e24501836e410f27b615d4

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Autor: Martin Wilhelm, Bettina Altmann, Mathieu Leclerc, Laurence de Leval, Ulrich Keller, Arnaud Jaccard, Emmanuel Gyan, Olivier Tournilhac, Peter Reimer, Maike Nickelsen, Martin Dreyling, Jacques-Olivier Bay, Karin Bilger, Bernd Metzner, Andreas Viardot, Laurence Sanhes, Murielle Roussel, Philippe Gaulard, Marita Ziepert, Noel Milpied, Gandhi Damaj, Norbert Schmitz, Friederike Braulke, Walter Lindemann, Eva Maria Wagner-Drouet, Alain Delmer, Bertram Glass, Guillaume Cartron, Thierry Lamy, Krimo Bouabdallah, Viola Poeschel, Frank Kroschinsky, Birte Friedrichs, Lorenz Truemper, David Sibon, Peter Dreger, Andreas Rosenwald, Christian Gisselbrecht, Mathias Haenel, Anne Banos, Gerald Wulf

Publikováno v: Blood
Blood, American Society of Hematology, 2021, ⟨10.1182/blood.2020008825⟩
Blood, 2021, 2020008825, ⟨10.1182/blood.2020008825⟩
Blood, American Society of Hematology, 2021, 2020008825, ⟨10.1182/blood.2020008825⟩

Standard first-line therapy for younger patients with peripheral T-cell lymphoma consists of six courses of CHOP or CHOEP consolidated by high-dose therapy and autologous stem cell transplantation (AutoSCT). We hypothesized that consolidative allogen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0f0e031c9b11d1bf5b292dc0c3843d1
https://hal.umontpellier.fr/hal-03163608/document

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Autor: Norbert Schmitz, Fabian Frontzek, Frank Kroschinsky, Peter Borchmann, Andreas Rosenwald, Georg Lenz, Andreas Viardot, Maike Nickelsen, Gerhard Held, Mathias Haenel, Bertram Glass, Bernd Metzner, Bettina Altmann, Martin Dreyling, Heike Horn, Martin Bentz, Annette M. Staiger, German Ott, Lorenz Truemper, Markus Loeffler, Marita Ziepert

Publikováno v: Blood. 136:5-6

Introduction:Considering the increasing numbers of lymphoma patients (pts) surviving long-term, late effects of current treatment strategies such as secondary (sec) malignancies gain increasing importance. Many treatment regimens used in pts with lym

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7c4904f410dda7ccac7575a30047ee0
https://doi.org/10.1182/blood-2020-138412

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial

Autor: Maike Nickelsen, Marita Ziepert, Mathias Haenel, Bettina Altmann, Andreas Viardot, Christian Schmidt, Birte Friedrichs, Andreas Rosenwald, Norbert Schmitz, Markus Loeffler, Bertram Glass, Georg Lenz, Christian Ruebe, Michael Pfreundschuh

Publikováno v: British journal of haematology. 184(5)

To further improve outcome in young high-risk patients with diffuse large B-cell lymphoma (DLBCL) the number of rituximab (R) infusions was doubled in combination with standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a863a84739d487153f5fab01fa00383b
https://pubmed.ncbi.nlm.nih.gov/30520013

INTENSIVE IMMUNOCHEMOTHERAPY (R-CHOEP) VS HIGH-DOSE IMMUNOCHEMOTHERAPY (R-MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A 10-YEAR LONG-TERM FOLLOW-UP

Autor: Bernd Metzner, M. Bentz, Georg Lenz, Andreas Rosenwald, Frank Kroschinsky, Peter Borchmann, Martin Dreyling, Marita Ziepert, Andreas Viardot, Bettina Altmann, Markus Löffler, German Ott, Gerhard Held, Maike Nickelsen, Norbert Schmitz, F. Frontzek, M. Hänel, B. Glaß, Lorenz Trümper, Annette M. Staiger

Publikováno v: Hematological Oncology. 37:431-432

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c6c397b612e1cd0748e8961da901177
https://doi.org/10.1002/hon.104_2631